Clinical trial
A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy
NCT02472145 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- August 4, 2015
- Completion date
- January 25, 2018
- Enrollment
- 326 (actual)
- Sites
- 81
Conditions
As the registry lists them; a condition with its own page is linked.